



GOOD NEWS: CAFFEINE CITRATE ORAL/IV SOLUTION (PEYONA™) AND GLYCOPYRROLATE ORAL SOLUTION (CUVPOSA™)

*The Goodman Pediatric Formulations Centre of the CHU Sainte-Justine (GPFC)
is excited to share good news on new pediatric formulations!*

PEYONA™

Caffeine citrate is one of the most prescribed drug in the present day neonatal intensive care unit, and has recently been approved for use in premature newborn for the short-term treatment of primary apnea in Canada. The intravenous and oral solution ampules of Peyona contain 20 mg of caffeine citrate, equivalent to 10 mg caffeine base. The arrival date of Peyona on the Canadian market is unknown at this time, but we will let you now as soon as we find out!

The GPFC had identified caffeine citrate on its priority list as a much-needed medicine in neonatology. Caffeine citrate solutions have been available in the US for over 20 years, and in Europe and Australia for at least 10 years to treat premature apnea. In Canada, during that period, caffeine citrate for injection or oral administration could only be accessed on a named patient basis through the Health Canada Special Access Program or through pharmacy compounding.

CUVPOSA™

We recently learned about the [INESSS notice to the Minister](#) regarding [Cuvposa](#). This medication has received Health Canada's approval in November 2017, but it has only appeared on INESSS list of recommended medications for the management of chronic severe sialorrhea in pediatric patients as of last October.

Access to another child-friendly medicine is certainly great news, but the fact that INESSS relied on the Goodman Pediatric Formulations Centre's recommendations to justify their decision is definitely a first and a major accomplishment for the centre.

Here is an excerpt of the INESSS notice (translated): "Adding glycopyrrolate on the list aligns with Health Canada's and the Quebec Order of Pharmacists' policies on non-sterile compounding drugs in a pharmaceutical setting aiming at prioritizing commercialized options, as well as with the Canadian Paediatric Society's and Goodman Pediatric Formulations Centre of the CHU Sainte-Justine's position statement on improving access to child-friendly medications".



CADTH has not yet provided their position regarding the reimbursement of glycopyrrolate oral solution.

Source:

Andrea Gilpin, Ph.D., MBA
General Manager, GPFC
514 345-4931, extension 3655
agilpin.cfpg@gmail.com
gpfccanada.com